HALO · Halozyme Therapeutics, Inc. · Earnings Call Transcripts & Audio
$110.40
-1.16 (-1.04%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$12.93B
Shares
113.50M
Volume · Sep 30
3.52M
Avg daily vol (3M)
2.16M
Halozyme Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Halozyme Therapeutics, Inc. (HALO), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲80.4%
$208.98M
$61.63M
'22 Q3
22-11-08
▲77.9%
$181.50M
$57.70M
'22 Q4
23-02-21
▲38.3%
$162.14M
$39.62M
'23 Q1
23-05-09
▲45.1%
$221.04M
$74.75M
'23 Q2
23-08-08
▲3.4%
$216.03M
$81.84M
'23 Q3
23-11-06
▲26.7%
$230.04M
$85.39M
'23 Q4
24-02-20
▲20.8%
$195.88M
$76.82M
'24 Q1
24-05-07
▲4.7%
$231.35M
$93.25M
'24 Q2
24-08-06
▲34.3%
$290.08M
$137.01M
'24 Q3
24-10-31
▲29.5%
$298.01M
$137.01M
'24 Q4
25-02-18
▲35.2%
$264.86M
$118.09M
'25 Q1
25-05-06
▲40.8%
$325.72M
$165.16M
'25 Q2
25-08-05
▲22.1%
$354.26M
$175.22M
'25 Q3
25-11-03
▲51.6%
$451.77M
−$141.59M
'25 Q4
26-01-28
▲42.2%
$376.71M
$150.05M
'26 Q1
26-05-11
LATEST
▲47.7%
$481.00M
$229.91M
'26 Q2
26-08-06
Conference
Investor event
2026-09-16
Halozyme Therapeutics, Inc. (HALO) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Halozyme Therapeutics, Inc. (HALO) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Halozyme Therapeutics, Inc. (HALO) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Confident tone
Royalty revenue growth and diversification
Litigation and IP risk (Merck/LTAGE patent dispute)
M&A and capital allocation
Revenue
$481.00M
▲ 47.7% YoY Diluted EPS
$1.90
▲ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Confident tone
ENHANZE royalty growth and commercial portfolio
Hypercon platform progress and partnerships
2029-plus revenue drivers and pipeline expansion
Revenue
$376.71M
▲ 42.2% YoY Diluted EPS
$1.22
▲ 31.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-01-28
Halozyme Therapeutics, Inc. (HALO) January 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-28
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Confident tone
Portfolio Expansion via Acquisitions
Pipeline and Development Plans
Revenue
$451.77M*
▲ 51.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
Confident tone
ENHANZE drug delivery technology
Elektrofi acquisition and Hypercon technology
DARZALEX subcutaneous performance
Revenue
$354.26M
▲ 22.1% YoY Diluted EPS
$1.43
▲ 36.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
Confident tone
ENHANZE Technology Platform
Merck Patent Litigation
DARZALEX Subcutaneous
Revenue
$325.72M
▲ 40.8% YoY Diluted EPS
$1.33
▲ 84.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Confident tone
ENHANZE blockbusters (DARZALEX, Phesgo, VYVGART Hytrulo)
Litigation (Merck/Keytruda, MDASE, PGR)
M&A and inorganic growth
Revenue
$264.86M
▲ 35.2% YoY Diluted EPS
$0.93
▲ 55% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-18
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Confident tone
DARZALEX subcutaneous with ENHANZE
VYVGART Hytrulo and CIDP expansion
Record 2024 financial performance
Revenue
$298.01M*
▲ 29.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-01-08
Halozyme Therapeutics, Inc. (HALO) January 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q3
2024-10-31
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
Confident tone
ENHANZE royalty growth and partner approvals
MDASE / modified hyaluronidase IP licensing
New target nominations and deal expansion
Revenue
$290.08M
▲ 34.3% YoY Diluted EPS
$1.05
▲ 72.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript
Confident tone
Wave 3 Product Approvals and Pipeline Progress
Collaboration and Milestone Revenue Cadence
Capital Allocation and M&A / Business Development
Revenue
$231.35M
▲ 4.7% YoY Diluted EPS
$0.72
▲ 28.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript
Confident tone
ENHANZE platform and high-volume auto-injector
Partner product approvals and launches
Regulatory progress and PDUFA dates
Revenue
$195.88M
▲ 20.8% YoY Diluted EPS
$0.60
▲ 106.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-20
Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript
Confident tone
ENHANZE pipeline expansion and Wave 3 readouts
Royalty revenue growth from key partnered products
FY2024 guidance and five-year financial outlook
Revenue
$230.04M*
▲ 26.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
Revenue
$216.03M
▲ 3.4% YoY Diluted EPS
$0.61
▲ 38.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Call Transcript
Revenue
$221.04M
▲ 45.1% YoY Diluted EPS
$0.56
▲ 250% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Halozyme Therapeutics, Inc. (HALO) Q1 2023 Earnings Call Transcript
Revenue
$162.14M
▲ 38.3% YoY Diluted EPS
$0.29
▼ 32.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Halozyme Therapeutics, Inc. (HALO) Q4 2022 Earnings Call Transcript
Revenue
$181.50M*
▲ 77.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Halozyme Therapeutics, Inc. (HALO) Q3 2022 Earnings Call Transcript
Revenue
$208.98M
▲ 80.4% YoY Diluted EPS
$0.44
▼ 70.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Halozyme Therapeutics, Inc. (HALO) Q2 2022 Earnings Call Transcript
Revenue
$152.37M
▲ 11.7% YoY Diluted EPS
$0.16
▼ 74.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Halozyme Therapeutics, Inc. (HALO) Q1 2022 Earnings Call Transcript
Revenue
$117.28M
▲ 31.7% YoY Diluted EPS
$0.43
▲ 126.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Halozyme Therapeutics, Inc. (HALO) Q4 2021 Earnings Call Transcript
Revenue
$102.00M*
▼ 16.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Halozyme Therapeutics, Inc. (HALO) Q3 2021 Earnings Call Transcript
Revenue
$115.83M
▲ 77.3% YoY Diluted EPS
$1.48
▲ 492% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Halozyme Therapeutics, Inc. (HALO) Q2 2021 Earnings Call Transcript
Revenue
$136.46M
▲ 147.1% YoY Diluted EPS
$0.62
▲ 226.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Halozyme Therapeutics, Inc. (HALO) Q1 2021 Earnings Call Transcript
Revenue
$89.02M
▲ 251.1% YoY Diluted EPS
$0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Halozyme Therapeutics, Inc. (HALO) Q4 2020 Earnings Call Transcript
Revenue
$121.70M
▲ 126.8% YoY Diluted EPS
$0.50
Gross margin
5.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Halozyme Therapeutics, Inc. (HALO) Q3 2020 Earnings Call Transcript
Revenue
$65.32M
▲ 41.3% YoY Diluted EPS
$0.25
Gross margin
5.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Halozyme Therapeutics, Inc. (HALO) Q2 2020 Earnings Call Transcript
Revenue
$55.22M
▲ 41.1% YoY Diluted EPS
$0.19
Gross margin
1.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Halozyme Therapeutics, Inc. (HALO) Q1 2020 Earnings Call Transcript
Revenue
$25.35M
▼ 55.5% YoY Diluted EPS
$-0.04
▼ 500% YoY Gross margin
9.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Halozyme Therapeutics, Inc. (HALO) Q4 2019 Earnings Call
Revenue
$53.66M
▼ 10.9% YoY Diluted EPS
$-0.24
Gross margin
11.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
21 filings
16 filers
Visit website
Investor relations